Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:8923 |
Name | skin melanoma |
Definition | A skin cancer that has_material_basis_in melanocytes. |
Source | DiseaseOntology.org |
Alt Ids | DOID:10043 DOID:10051 DOID:0050609 DOID:10046 DOID:10052 DOID:10055 DOID:8922 |
Path | disease disease of cellular proliferation cancer organ system cancer integumentary system cancer skin cancer skin melanoma |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01107665 | Phase II | Paclitaxel + Pazopanib | Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma | Completed | USA | 0 |
NCT01693068 | Phase II | Dacarbazine Pimasertib | Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma | Completed | USA | SWE | NZL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CHE | BEL | AUS | 1 |
NCT01989585 | Phase Ib/II | Dabrafenib + Navitoclax + Trametinib Dabrafenib + Trametinib | Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma | Active, not recruiting | USA | 0 |
NCT02203604 | Phase II | Aldesleukin + Ipilimumab | High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery | Terminated | USA | 0 |
NCT02346955 | Phase I | CM-24 CM-24 + Pembrolizumab | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | Terminated | USA | ISR | 0 |
NCT02535078 | Phase Ib/II | Durvalumab Tebentafusp Tremelimumab | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma | Withdrawn | USA | 0 |
NCT02581930 | Phase II | Ibrutinib | Ibrutinib in Treating Patients With Refractory Stage IV Cutaneous Melanoma | Active, not recruiting | USA | 0 |
NCT02645149 | Phase II | Trametinib Pazopanib Ceritinib Ribociclib + Trametinib | Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel) | Recruiting | AUS | 0 |
NCT02680184 | Phase I | Pembrolizumab + Vidutolimod | Clinical Study of CMP-001 in Combination With Pembrolizumab | Completed | USA | 0 |
NCT02731729 | Phase II | Ipilimumab Nivolumab | Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy | Completed | USA | 0 |
NCT02748564 | Phase II | Aldesleukin + Pembrolizumab | Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | Terminated | USA | 0 |
NCT02818023 | Phase I | Cobimetinib + Pembrolizumab + Vemurafenib | Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma | Terminated | USA | 0 |
NCT02829099 | Phase I | JNJ-64457107 | A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors | Completed | ISR | ESP | 0 |
NCT02938299 | Phase III | Daromun + Onfekafusp alfa | Neoadjuvant L19IL2/L19TNF- Pivotal Study (Pivotal) | Active, not recruiting | POL | ITA | FRA | DEU | 0 |
NCT03084640 | Phase Ib/II | Pembrolizumab + Vidutolimod | Phase 1b Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Subjects With Advanced Melanoma | Completed | USA | 0 |
NCT03089606 | Phase II | Pembrolizumab | Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker | Completed | USA | 0 |
NCT03235245 | Phase II | Binimetinib + Encorafenib Ipilimumab + Nivolumab | Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN) | Active, not recruiting | POL | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | 0 |
NCT03278665 | Phase Ib/II | Domatinostat + Pembrolizumab | 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy (SENSITIZE) | Completed | ITA | DEU | 0 |
NCT03340129 | Phase II | Ipilimumab + Nivolumab | Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (ABC-X) | Recruiting | NOR | AUS | 0 |
NCT03405155 | Phase II | Nivolumab | Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT03551626 | Phase III | Dabrafenib + Trametinib | Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus) | Completed | TUR | SWE | SVN | SVK | POL | NOR | LVA | LTU | ITA | ISR | HUN | GRC | GBR | FRA | FIN | CZE | CAN | BRA | AUS | ARG | 3 |
NCT03553836 | Phase III | Pembrolizumab | Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) | Active, not recruiting | USA | POL | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUS | 3 |
NCT03618641 | Phase II | Nivolumab + Vidutolimod | CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease | Completed | USA | 0 |
NCT03693612 | Phase Ib/II | GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab | GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors | Completed | USA | CAN | AUS | 0 |
NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Completed | USA | NLD | GBR | FRA | FIN | ESP | 0 |
NCT03754179 | Phase Ib/II | Dabrafenib + Hydroxychloroquine + Trametinib | Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma (COMBI-R2) | Unknown status | BEL | 0 |
NCT03817125 | Phase I | Nivolumab + SER-401 Vancomycin Nivolumab | Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW) | Completed | USA | 0 |
NCT03829254 | Phase Ib/II | NUC-7738 NUC-7738 + Pembrolizumab | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | Recruiting | GBR | 0 |
NCT03842943 | Phase II | Pembrolizumab + Talimogene laherparepvec | Neoadjuvant Combination Immunotherapy for Stage III Melanoma | Recruiting | USA | 0 |
NCT03864042 | Phase I | Caffeine + Dextromethorphan + Losartan + Midazolam + Omeprazole Modafinil Bupropion + Rosuvastatin Binimetinib + Encorafenib | Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors | Completed | USA | NLD | ESP | CAN | BEL | 0 |
NCT03875079 | Phase I | Pembrolizumab + RO6874281 | A Phase IB Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant Targeting Fibroblast Activation Protein-A, In Combination With Pembrolizumab (Anti-Pd-1), In Participants With Previously Untreated Advanced And/Or Metastatic Melanoma | Completed | USA | FRA | ESP | CAN | BEL | AUS | 1 |
NCT03897881 | Phase II | mRNA-4157 + Pembrolizumab Pembrolizumab | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Patients With High-Risk Melanoma (KEYNOTE-942) | Recruiting | USA | AUS | 0 |
NCT03898908 | Phase II | Binimetinib + Encorafenib | Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain (EBRAIN-MEL) | Active, not recruiting | ESP | 0 |
NCT03947385 | Phase Ib/II | IDE196 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Recruiting | USA | CAN | AUS | 0 |
NCT03972046 | Phase II | Dabrafenib + Talimogene laherparepvec + Trametinib | Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma | Withdrawn | USA | 0 |
NCT03991741 | Phase I | Aldesleukin | Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors | Recruiting | USA | 0 |
NCT04007588 | Phase II | Ipilimumab + Nivolumab Nivolumab Linrodostat + Nivolumab | A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma | Withdrawn | USA | 0 |
NCT04020809 | Phase I | Atezolizumab | Neoadjuvant Atezolizumab in Cutaneous Melanoma | Active, not recruiting | USA | 0 |
NCT04042480 | Phase I | SGN-CD228A | A Study of SGN-CD228A in Advanced Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | 0 |
NCT04042506 | Phase II | Nivolumab | SBRT as a Vaccination for Metastatic Melanoma | Withdrawn | USA | 0 |
NCT04074096 | Phase II | Binimetinib + Encorafenib + Pembrolizumab | Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis (BEPCOME-MB) | Active, not recruiting | FRA | 0 |
NCT04099251 | Phase III | Nivolumab | Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate76K) | Active, not recruiting | USA | SWE | ROU | POL | NOR | NLD | ITA | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 0 |
NCT04130516 | Phase Ib/II | LNS8801 LNS8801 + Pembrolizumab | Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab | Recruiting | USA | 0 |
NCT04135352 | Phase I | Pembrolizumab + V938 | A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001) | Terminated | USA | ISR | CAN | 0 |
NCT04136834 | Phase I | Pegtomarginase | A Phase I Open-label Study for Subjects With Advanced Malignancies (PT01) | Unknown status | USA | 0 |
NCT04139902 | Phase II | Cobolimab + Dostarlimab-gxly Dostarlimab-gxly | PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042) | Recruiting | USA | 0 |
NCT04207086 | Phase II | Lenvatinib + Pembrolizumab Pembrolizumab | A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma (Neo PeLe) | Active, not recruiting | AUS | 0 |
NCT04221438 | Phase II | Binimetinib + Encorafenib | Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement | Active, not recruiting | USA | 0 |
NCT04250597 | Phase I | GNX102 | Study of GNX102 in Patients With Advanced Solid Tumors | Terminated | USA | 1 |
NCT04261439 | Phase I | NIZ985 NIZ985 + Spartalizumab | A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab | Terminated | USA | ITA | ESP | DEU | BEL | 2 |
NCT04301011 | Phase Ib/II | TBio-6517 Pembrolizumab + TBio-6517 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (RAPTOR) | Terminated | USA | CAN | 1 |
NCT04338685 | Phase I | RO7119929 + Tocilizumab | A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases | Completed | USA | ESP | DNK | 3 |
NCT04356729 | Phase II | Atezolizumab + Bevacizumab | A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma | Recruiting | USA | 0 |
NCT04375527 | Phase II | Binimetinib + Nivolumab | Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma | Recruiting | USA | 0 |
NCT04381650 | Phase Ib/II | Pembrolizumab + Subasumstat | A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | POL | LVA | LTU | HRV | CHE | BRA | 2 |
NCT04401995 | Phase II | Nivolumab Nivolumab + Vidutolimod | Study of TLR9 Agonist CMP-001 in Combination With Nivolumab vs. Nivolumab | Completed | USA | 0 |
NCT04410445 | Phase III | Nivolumab Nivolumab + NKTR-214 | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12) | Terminated | USA | ROU | POL | NZL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | AUT | AUS | 2 |
NCT04455503 | Phase Ib/II | EVX-02 + Nivolumab | Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 | Terminated | AUS | 0 |
NCT04493203 | Phase II | Axitinib + Nivolumab | Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma | Active, not recruiting | USA | 0 |
NCT04495010 | Phase II | Nivolumab Ipilimumab + Nivolumab | Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants (CheckMate 7UA) | Withdrawn | USA | SWE | POL | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CHE | BRA | BEL | AUT | AUS | 1 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04526899 | Phase II | Cemiplimab BNT111 BNT111 + Cemiplimab | Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD1-refractory/Relapsed, Unresectable Stage III or IV Melanoma | Active, not recruiting | USA | POL | ITA | GBR | ESP | DEU | AUS | 0 |
NCT04551352 | Phase I | RO7293583 + Tocilizumab Obinutuzumab + RO7293583 + Tocilizumab | A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas | Completed | USA | ESP | DNK | CAN | BEL | AUS | 0 |
NCT04570332 | Phase II | BO-112 + Pembrolizumab | BO-112 With Pembrolizumab in Unresectable Malignant Melanoma (SPOTLIGHT203) | Active, not recruiting | FRA | ESP | 0 |
NCT04577807 | Phase II | PVSRIPO + unspecified PD-1 antibody PVSRIPO | PVSRIPO With or Without Immune Checkpoint Blockade in Patients With Advanced PD-1 Refractory Melanoma | Active, not recruiting | USA | 0 |
NCT04592653 | Phase Ib/II | ALKS 4230 ALKS 4230 + Pembrolizumab | Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) | Active, not recruiting | USA | ESP | 0 |
NCT04609566 | Phase II | Brentuximab vedotin + Pembrolizumab | Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04620603 | Phase Ib/II | Nivolumab | Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer | Recruiting | USA | 0 |
NCT04657991 | Phase III | Pembrolizumab Binimetinib + Encorafenib + Pembrolizumab | A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma | Active, not recruiting | USA | TUR | SVK | POL | NZL | NOR | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | ARG | 4 |
NCT04697576 | Phase I | Nivolumab Pembrolizumab Ipilimumab | Intralesional Influenza Vaccine for the Treatment of Stage I, II, and IV Melanoma | Recruiting | USA | 0 |
NCT04703426 | Phase II | Pembrolizumab + Sargramostim | Sargramostim (GM-CSF) + PD-1 | Withdrawn | 0 | |
NCT04706962 | Phase I | TH1902 | TH1902 in Patients With Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04759846 | Phase I | Binimetinib + Encorafenib | Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma | Withdrawn | ITA | ESP | CZE | 0 |
NCT04830124 | Phase II | ALKS 4230 | Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6 (ARTISTRY-6) | Recruiting | USA | ITA | GBR | ESP | CAN | AUS | 2 |
NCT04835805 | Phase I | Belvarafenib + Cobimetinib + Nivolumab Belvarafenib + Cobimetinib Belvarafenib | A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. | Active, not recruiting | USA | NOR | DEU | CAN | AUS | 1 |
NCT04901988 | Phase II | Nivolumab | Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION (DETECTION) | Terminated | GBR | 0 |
NCT04930783 | Phase I | CDX-301 + Nivolumab + Poly ICLC | NeoVax + CDX-301 and Nivolumab in Advanced Melanoma | Recruiting | USA | 0 |
NCT04958239 | Phase I | BI 765179 + Ezabenlimab BI 765179 | A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer | Recruiting | USA | NLD | ITA | ISR | FRA | ESP | DEU | CZE | BRA | BEL | AUS | 4 |
NCT04995094 | Phase II | Pembrolizumab Pembrolizumab + PGG beta-glucan | Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma | Withdrawn | USA | 0 |
NCT05050006 | Phase II | ITIL-168 | ITIL-168 in Advanced Melanoma (DELTA-1) | Terminated | USA | GBR | CAN | 0 |
NCT05060003 | Phase II | Atezolizumab Atezolizumab + Tiragolumab | Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection | Terminated | USA | 0 |
NCT05061017 | Phase II | Cyclophosphamide + Nivolumab + PG545 Nivolumab + PG545 | Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) | Completed | USA | 0 |
NCT05061134 | Phase II | Ceralasertib + Durvalumab Ceralasertib | A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition (MONETTE) | Active, not recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 1 |
NCT05069935 | Phase I | Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Terminated | USA | 0 |
NCT05086692 | Phase Ib/II | MDNA11 + Pembrolizumab | A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) | Recruiting | USA | CAN | AUS | 1 |
NCT05098210 | Phase I | NeoVax + Nivolumab + Poly ICLC | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer | Recruiting | USA | 0 |
NCT05130177 | Phase II | AB154 + Zimberelimab | Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma | Recruiting | USA | 0 |
NCT05200143 | Phase II | Cabozantinib + Ipilimumab + Nivolumab | Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma | Terminated | USA | 0 |
NCT05200559 | Phase Ib/II | E7777 + Pembrolizumab | T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05203172 | FDA approved | Encorafenib Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib Binimetinib + Cetuximab + Encorafenib Binimetinib | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | Recruiting | USA | SVK | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUS | 4 |
NCT05270044 | Phase III | Binimetinib + Encorafenib | Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD) | Active, not recruiting | SWE | ROU | POL | NOR | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 3 |
NCT05280314 | Phase II | IO102-IO103 + Pembrolizumab | Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab in Patients With Resectable Tumors | Recruiting | USA | FRA | ESP | DNK | DEU | AUS | 0 |
NCT05315258 | Phase II | Tebentafusp | Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma (TebeMRD) | Recruiting | GBR | 0 |
NCT05354323 | Phase I | NECVAX-NEO1 | NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors | Recruiting | LTU | 0 |
NCT05415072 | Phase Ib/II | DYP688 | A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas | Recruiting | USA | NLD | FRA | ESP | DEU | CHE | AUS | 0 |
NCT05418972 | Phase II | Nivolumab and relatlimab-rmbw | A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma (Neo ReNi II) | Recruiting | AUS | 0 |
NCT05479812 | Phase I | WTX-124 Pembrolizumab + WTX-124 | Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05482074 | Phase II | Olaparib | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | Withdrawn | 0 | |
NCT05492682 | Phase I | Cyclophosphamide + Pembrolizumab + PeptiCRAd-1 | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | Recruiting | DEU | 0 |
NCT05529316 | Phase II | Botensilimab | A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma | Suspended | USA | ITA | GBR | FRA | ESP | DEU | CHE | BRA | BEL | 1 |
NCT05533697 | Phase Ib/II | mRNA-4359 + Pembrolizumab mRNA-4359 | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | ESP | AUS | 0 |
NCT05544929 | Phase I | KFA115 KFA115 + Pembrolizumab | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | Recruiting | USA | ITA | ESP | DEU | CAN | 4 |
NCT05571839 | Phase I | SGN-BB228 | A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors | Recruiting | USA | GBR | FRA | DEU | CHE | CAN | 0 |
NCT05572463 | Phase Ib/II | IBI110 + Sintilimab | A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma | Withdrawn | USA | GBR | FRA | ESP | DEU | CHE | AUS | 0 |
NCT05576077 | Phase I | Pembrolizumab + TBio-4101 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (STARLING) | Recruiting | USA | CAN | 0 |
NCT05578872 | Phase Ib/II | ANV419 + Ipilimumab ANV419 + Pembrolizumab ANV419 | A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (ANV419-101). | Recruiting | USA | ITA | FRA | ESP | DEU | 0 |
NCT05580770 | Phase Ib/II | BGB3245 + PD-0325901 | Mirdametinib + BGB-3245 in Advanced Solid Tumors | Active, not recruiting | USA | AUS | 0 |
NCT05620914 | Phase I | Patritumab deruxtecan | A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) | Not yet recruiting | USA | 0 |
NCT05628883 | Phase I | Cyclophosphamide + Fludarabine TBio-4101 Aldesleukin | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | Recruiting | USA | 0 |
NCT05665595 | Phase III | Pembrolizumab MK-7684A | A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) | Active, not recruiting | USA | TUR | SWE | POL | NZL | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 7 |
NCT05709821 | Phase Ib/II | Pembrolizumab IMM60 IMM60 + Pembrolizumab | IMM60 and Pembrolizumab in Melanoma and NSCLC | Terminated | USA | GBR | ESP | 0 |
NCT05764395 | Phase II | Pembrolizumab + Rigosertib | Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors | Suspended | USA | 0 |
NCT05767879 | Phase II | Binimetinib + Encorafenib | (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma | Recruiting | NLD | 0 |
NCT05836324 | Phase I | INCA33890 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DNK | CHE | 0 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT05869539 | Phase I | ANV419 + tumor infiltrating lymphocytes | ACT-TIL and ANV419 for Advanced Melanoma. (BaseTIL-03M) | Recruiting | CHE | 0 |
NCT05879822 | Phase II | INCB099280 | A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive | Active, not recruiting | TUR | ROU | NZL | HUN | GRC | BRA | 3 |
NCT05909995 | Phase I | INCB099280 + Ipilimumab | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors | Active, not recruiting | USA | CAN | 1 |
NCT05926960 | Phase II | Binimetinib + Encorafenib + Pembrolizumab Ipilimumab + Nivolumab | A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma (PORTSIDE) | Active, not recruiting | SVK | POL | ITA | GBR | ESP | DEU | CZE | 0 |
NCT05933577 | Phase III | Pembrolizumab mRNA-4157 + Pembrolizumab | A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) | Active, not recruiting | USA | TUR | SWE | POL | NZL | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUS | ARG | 7 |
NCT06030037 | Phase II | Lenvatinib + Pembrolizumab | Pembrolizumab/Lenvatinib With and Without Responder-derived FMT in Relapsed/Refractory Melanoma | Not yet recruiting | USA | 0 |
NCT06099782 | Phase II | MK-3475A Pembrolizumab | A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) | Recruiting | USA | TUR | POL | NZL | FRA | AUS | ARG | 3 |
NCT06157099 | Phase II | Atorvastatin | Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma | Recruiting | USA | 0 |
NCT06171178 | Phase I | ASP1012 + Pembrolizumab ASP1012 | A Study of ASP1012 in Adults With Solid Tumors | Recruiting | USA | 0 |
NCT06172478 | Phase II | Patritumab deruxtecan | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 2 |
NCT06190951 | Phase II | Pembrolizumab Cemiplimab Cemiplimab + Fianlimab | A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma | Recruiting | USA | 0 |
NCT06194929 | Phase Ib/II | Defactinib + Encorafenib + RO5126766 Defactinib + RO5126766 | Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma (DETERMINE) | Recruiting | USA | 0 |
NCT06240143 | Phase Ib/II | Ipilimumab + Nivolumab | Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma (MARIANE) | Recruiting | NLD | 0 |
NCT06250335 | Phase II | Ipilimumab + Nivolumab | Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients | Recruiting | USA | 0 |
NCT06264180 | Phase III | Nab-paclitaxel Nivolumab + RP1 Paclitaxel Nivolumab and relatlimab-rmbw Nivolumab Dacarbazine Pembrolizumab Temozolomide | VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3) | Recruiting | USA | 0 |
NCT06331598 | Phase II | Atezolizumab Atezolizumab + Tiragolumab | A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator) | Recruiting | ESP | 0 |
NCT06346067 | Phase III | LXH 254 + Trametinib Trametinib Dacarbazine Temozolomide | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | Recruiting | USA | NLD | GBR | FRA | ESP | CZE | CAN | AUS | 0 |
NCT06470763 | Phase Ib/II | ANV600 ANV600 + Pembrolizumab | A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1) | Recruiting | USA | NLD | FRA | ESP | DEU | CHE | 0 |
NCT06594991 | Phase II | Cemiplimab + Fianlimab + Ipilimumab | A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma | Recruiting | USA | 0 |
NCT06598371 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin + KSQ-004EX KSQ-004EX | A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors | Not yet recruiting | USA | 0 |
NCT06651151 | Phase II | LTX-315 + Pembrolizumab | NeoLIPA: Neoadjuvant LTX-315 in Combination With Pembrolizumab in Resectable Stage III/IV Melanoma (NeoLIPA) | Recruiting | NOR | 0 |